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Introduction

32
The innate immune system provides the first line of defence against invading pathogens such 33 as viruses. Cells are armed with pattern recognition receptors (PRRs) that recognise 34 pathogen-associated molecular patterns (PAMPs), such as viral nucleic acids, and lead to the stimulated genes (ISGs) and inflammatory chemokines including CXCL-10, IFIT-2 (also 122 known as ISG54) and CXCL-2 in response to a range of stimuli, including transfection of 123 herring-testis DNA (HT-DNA), exposure to 2'3'-cGAMP and infection by Sendai virus (Suppl. 
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Infection of PMA-treated THP-1 shSAMHD1 cells with HIV-1 GFP that had been produced in 127 the presence of increasing doses of LPV led to a virus and LPV dose-dependent increase in positive control for ruxolitinib activity (Fig. 1H, Suppl. Fig. 2C ). Importantly, viral DNA 152 production, measured by qPCR in infected PMA-treated THP-1 shSAMHD1 cells, was not 153 changed by increasing LPV dose suggesting that PI inhibited HIV-1 makes normal levels of 154 DNA but fails to protect PAMPs from innate immune sensors (Fig. 1I ).
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To test whether PI inhibition of HIV-1 caused similar innate immune activation in primary 1998). Increasing the proportion of the ∆CA-SP1 mutant increased the presence of uncleaved 182 CA-SP1 detected by immunoblot ( Fig. 2A) . Defective cleavage was accompanied by a 183 modest decrease in infectivity on U87 cells (Fig. 2B ).
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As with HIV-1 GFP produced in the presence of PIs, infection of PMA-treated THP-1 186 shSAMHD1 cells with the HIV-1 GFP ∆CA-SP1 mutants led to a ∆CA-SP1 dose-dependent 187 increase in the expression of CXCL-10 ( Fig. 2D) and MxA mRNA ( Fig. 2E) , and CXCL-10 at response, evidenced by suppression of IFIT1-luc by ruxolitinib ( Fig. 2H ). In the IFIT1-luc cells 198 ∆CA-SP1 mutation did not impact infection levels (Suppl. Fig. 4A -C) and neither did ruxolitinib 199 treatment (Suppl. Fig. 4C ). We propose that during single round infection the virus has 200 already integrated by the time IFN is produced, thus explaining why ruxolitinib has no impact 201 on the percentage of GFP positive cells. Together these data support our hypothesis that 202 disruption of Gag maturation yields viral particles that fail to shield PAMP from innate 
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Viral DNA of maturation defective HIV-1 is sensed by cGAS and STING
234
To investigate which innate sensors were involved in detecting cleavage defective HIV-1, we 235 infected cells that had been genetically manipulated by CRISPR/Cas 9 technology to lack the 
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To corroborate data obtained in the CRISPR cell lines, infection assays were also repeated in 257 THP-1 Dual reporter cells in the presence of the recently available STING inhibitor H151 258 (Haag, Gulen et al., 2018) . ISG induction by 12.5 nM DRV-treated or HIV-1 GFP bearing 90%
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∆CA-SP1 was greatly reduced by the presence of H151 ( Fig. 4I ), further supporting a role for 260 DNA sensing in the detection of maturation defective HIV-1. As expected, IRF reporter activity 261 was also suppressed by ruxolitinib ( Fig. 4I 
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As a measure of HIV-1 core integrity we tested the ability of the maturation defective viruses 
294
We therefore hypothesised that PF-74 treated HIV-1 may activate a DNA-sensing dependent 295 innate immune response. To test this, we infected THP-1 IFIT-1 reporter cells with increasing Fig. 8A ). Finally, we were able to demonstrate that innate sensing of PF-74- 
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and had reduced capacity to saturate the restriction factor TRIM5α in an abrogation-of-327 restriction assay, indicative of altered stability/capsid integrity ( Fig. 5 ). Importantly, when 328 these viruses were used to infect macrophages they induced a potent IFN response that was 329 not observed on infection with untreated or WT HIV-1 ( Fig. 1, Fig. 2 , Suppl. Fig. 3 ). Innate 330 immune responses were almost entirely dependent on viral reverse transcription ( Fig. 3 ) and 331 the cellular DNA sensing machinery comprising cGAS and STING ( Fig. 4) , consistent with 332 viral DNA being the most important PAMP in these experiments. As a third approach our 333 results were corroborated using the capsid targeting small molecule inhibitor PF-74, which 334 has been proposed to accelerate capsid opening (Marquez et al., 2018) . Treatment of HIV-1 335 with PF-74 also caused a DNA-sensing dependent IFN response ( Fig. 6 ). Together these 336 data support a model in which the WT HIV-1 core remains intact as it traverses the 337 cytoplasm, thus protecting viral DNA from detection by cGAS. Conversely, disruption of 338 capsid maturation or integrity, either chemically or genetically, yields particles that fail to 339 conceal viral DNA and thus activate a cGAS-dependent type 1 IFN response (Suppl. Fig. 9 ).
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We hypothesise that HIV-1 has evolved to cloak viral DNA synthesis within an intact 
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Genome copy/RT products measurements
506
For viral genome copy measurements RNA was extracted from 2 µl sucrose purified virus 507 using the RNeasy mini kit (QIAgen). The RNA was then treated with TURBO DNase (Thermo
508
Fisher Scientific) and subjected to reverse transcription using Superscript III reverse 509 transcriptase and random hexamers according to the manufacturer's protocol (Invitrogen).
510
Genome copies were then measured by Taqman qPCR using primers against GFP (see 511 below). For RT product measurements DNA was extracted from 5x10 5 infected cells using the 
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These data were then normalised to genomes/ml data calculated by qPCR to account for 857 variations in viral production. Data are presented as mean ± SD from three separate titrations 
1005
(1.7×10 6 -3.8×10 9 genomes/ml). Rescue of GFP infectivity was assessed by flow cytometry.
1006
Data are presented as singlet % GFP values and two repeats of the experiment are shown. 
